CN113329758A - 转铁蛋白受体靶向肽 - Google Patents

转铁蛋白受体靶向肽 Download PDF

Info

Publication number
CN113329758A
CN113329758A CN201980089966.8A CN201980089966A CN113329758A CN 113329758 A CN113329758 A CN 113329758A CN 201980089966 A CN201980089966 A CN 201980089966A CN 113329758 A CN113329758 A CN 113329758A
Authority
CN
China
Prior art keywords
seq
peptide
tfr
composition
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089966.8A
Other languages
English (en)
Chinese (zh)
Inventor
Z·克鲁克
M-Y·布鲁斯耐克
J·奥尔森
A·J·梅瑞
尹春风
G·G·郝平
R·斯特朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Cancer Research Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CN113329758A publication Critical patent/CN113329758A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
CN201980089966.8A 2018-12-14 2019-12-13 转铁蛋白受体靶向肽 Pending CN113329758A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779885P 2018-12-14 2018-12-14
US62/779,885 2018-12-14
US201962836520P 2019-04-19 2019-04-19
US62/836,520 2019-04-19
PCT/US2019/066376 WO2020124032A1 (en) 2018-12-14 2019-12-13 Transferrin receptor targeting peptides

Publications (1)

Publication Number Publication Date
CN113329758A true CN113329758A (zh) 2021-08-31

Family

ID=71077078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089966.8A Pending CN113329758A (zh) 2018-12-14 2019-12-13 转铁蛋白受体靶向肽

Country Status (8)

Country Link
US (1) US20220048961A1 (https=)
EP (1) EP3893913B1 (https=)
JP (2) JP7664158B2 (https=)
CN (1) CN113329758A (https=)
AU (1) AU2019398467A1 (https=)
CA (1) CA3120466A1 (https=)
IL (1) IL283839A (https=)
WO (1) WO2020124032A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160408A (zh) * 2022-06-29 2022-10-11 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981A (zh) * 2022-08-18 2023-04-07 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
WO2023061502A1 (zh) * 2021-10-15 2023-04-20 苏州生物医药转化工程中心 一种双特异性结合分子
CN120459270A (zh) * 2025-05-16 2025-08-12 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN111647048B (zh) * 2020-06-22 2021-04-02 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
US12076364B2 (en) 2020-06-22 2024-09-03 Kunming Institute Of Zoology, Chinese Academy Of Sciences Use of interference peptide in preparation of anti-SARS-CoV-2 medicament
JP2022014707A (ja) * 2020-07-07 2022-01-20 東亞合成株式会社 キャリアペプチドフラグメントおよびその利用
CN116075524A (zh) * 2020-07-30 2023-05-05 华盛顿大学 转铁蛋白受体结合蛋白
AU2021386254A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Compositions and methods for selective depletion of target molecules
WO2022180628A1 (en) * 2021-02-23 2022-09-01 Ichilov Tech Ltd. Fusion proteins for treating cns diseases
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
JPWO2023022234A1 (https=) * 2021-08-19 2023-02-23
CN118556069A (zh) * 2021-10-01 2024-08-27 首尔大学校产学协力团 用于穿透血脑屏障的肽及其用途
EP4626906A1 (en) * 2022-11-29 2025-10-08 Vacino Biotech Co., Ltd. Transporter peptides and application thereof
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
WO2024238304A2 (en) * 2023-05-12 2024-11-21 University Of Washington Improved transferrin receptor binding proteins
AU2024329222A1 (en) * 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025096245A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Design rules for endosomal escape
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115824A1 (en) * 2000-11-30 2002-08-22 Engler Jeffrey A. Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20110256156A1 (en) * 2007-10-03 2011-10-20 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
CN104520325A (zh) * 2012-05-21 2015-04-15 霍夫曼-拉罗奇有限公司 用于提高血脑屏障转运的安全性的方法
CN107810199A (zh) * 2015-06-24 2018-03-16 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062602A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
CA2864126A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
CA3033082A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115824A1 (en) * 2000-11-30 2002-08-22 Engler Jeffrey A. Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20110256156A1 (en) * 2007-10-03 2011-10-20 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
US20130177580A1 (en) * 2007-10-03 2013-07-11 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
CN104520325A (zh) * 2012-05-21 2015-04-15 霍夫曼-拉罗奇有限公司 用于提高血脑屏障转运的安全性的方法
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
CN107810199A (zh) * 2015-06-24 2018-03-16 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023061502A1 (zh) * 2021-10-15 2023-04-20 苏州生物医药转化工程中心 一种双特异性结合分子
CN115160408A (zh) * 2022-06-29 2022-10-11 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981A (zh) * 2022-08-18 2023-04-07 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
CN120459270A (zh) * 2025-05-16 2025-08-12 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Also Published As

Publication number Publication date
JP2022513798A (ja) 2022-02-09
JP2025038018A (ja) 2025-03-18
EP3893913A1 (en) 2021-10-20
WO2020124032A1 (en) 2020-06-18
AU2019398467A1 (en) 2021-06-24
US20220048961A1 (en) 2022-02-17
EP3893913B1 (en) 2025-03-26
CA3120466A1 (en) 2020-06-18
IL283839A (en) 2021-07-29
JP7664158B2 (ja) 2025-04-17
EP3893913A4 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP7664158B2 (ja) トランスフェリン受容体標的ペプチド
US20230151068A1 (en) Peptide compositions and methods of use thereof for disrupting tead interactions
US20250326866A1 (en) Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
HK1198173A1 (en) Potent and selective inhibitors of nav1.3 and nav1.7
US20180371033A1 (en) Therapeutic peptides and methods of use thereof
US11827687B2 (en) Synthetic somatostatin receptor ligands
US11046739B2 (en) BH4 stabilized peptides and uses thereof
CN107847554A (zh) 治疗性肽及其使用方法
KR20260026052A (ko) Dll3 표적화 펩티드 및 이의 구성체
KR20260026051A (ko) Dll3 표적화 펩티드 및 이의 구성체
KR20220143701A (ko) 돌연변이체 ras 단백질을 표적화하는 분자
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
CN117615774A (zh) Pd-l1结合肽和肽复合物及其使用方法
Parlak Peptide-based drug systems

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Washington State

Applicant after: Fred Hutchinson Cancer Center

Address before: Washington State

Applicant before: Seattle Cancer Research Center

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221031

Address after: Washington State

Applicant after: Seattle Cancer Research Center

Address before: Washington State

Applicant before: FRED HUTCHINSON CANCER RESEARCH CENTER